July 8, 2026 FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
July 8, 2026 AI-Powered Robotics Set to Unlock US$150 Billion Opportunity as Foundation Models Transform Automation